Dr. Montaner was the key driver in the discovery of highly active antiretroviral therapy (HAART), a game changer which helps to reduce viral load in HIV patients. HAART dramatically reduces the risk of spreading HIV, while improving the health and longevity of patients on treatment.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
